Literature DB >> 9501404

IVIG adverse reactions: potential role of cytokines and vasoactive substances.

A Bagdasarian1, S Tonetta, W Harel, R Mamidi, Y Uemura.   

Abstract

BACKGROUND AND OBJECTIVES: A clinical study was conducted to determine the effect of IVIG infusion rates on adverse experiences (AE) and on serum levels of cytokines and vasoactive substances.
MATERIALS AND METHODS: Forty-two healthy volunteers were randomized into 3 groups with maximum IVIG infusion rates of 0.04, 0.06, and 0.08 ml/kg/min, and a final dose of 0.5 g IgG/kg body weight.
RESULTS: Adverse reactions were noted only at the highest infusion rate of 0.08 ml/kg/min, except in 1 subject infused at 0.06 ml/kg/min. There were significant increases in IL-6 (p = 0.011) and thromboxane B2 (p = 0.007) in AE subjects as compared to non-AE subjects.
CONCLUSION: IVIG-induced adverse reactions occur more often with rapid infusion rates and may be mediated by elevated levels of inflammatory cytokines and vasoactive substances.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9501404

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  9 in total

Review 1.  Adverse effects of intravenous immunoglobulin therapy.

Authors:  U E Nydegger; M Sturzenegger
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

2.  Increased risk of adverse events when changing intravenous immunoglobulin preparations.

Authors:  R Ameratunga; J Sinclair; J Kolbe
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

3.  Immune globulin subcutaneous (human) vivaglobin: for the treatment of primary immunodeficiency diseases.

Authors: 
Journal:  P T       Date:  2009-06

4.  An immune globulin intravenous (human), 10% liquid privigen: for the treatment of primary immunodeficiency diseases.

Authors: 
Journal:  P T       Date:  2009-06

Review 5.  Adverse effects of treatment with intravenous immunoglobulins for neurological diseases.

Authors:  Matthias Wittstock; Uwe K Zettl
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

6.  A clinical cardiology perspective of thrombophilias.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

Review 7.  Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.

Authors:  Peter D Han; Russell D Cohen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Postintravenous immunoglobulin stroke in a toddler with Down syndrome: a diagnostic challenge.

Authors:  Teck-Hock Toh; Everlyn Coxin Siew; Chae-Hee Chieng; Hussain Imam Mohd Ismail
Journal:  BMJ Case Rep       Date:  2020-05-18

Review 9.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.